Advanced search
Publication Cover
Substance Use & Misuse Volume 59, 2024 - Issue 2
Submit an article Journal homepage
1,019
Views
0
CrossRef citations to date
0
Altmetric
Note

The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants

O. Trent Halla Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center Talbot Hall, Columbus, OH, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7067-763XView further author information
ORCID Icon,
Parker Entrupa Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center Talbot Hall, Columbus, OH, USAView further author information
,
Katie Farabeeb Bon Secours Mercy Health, Greenville, SC, USAView further author information
,
Hannah Qina Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center Talbot Hall, Columbus, OH, USAView further author information
,
Hafsah Rizvia Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center Talbot Hall, Columbus, OH, USAView further author information
,
Johnathan Rauscha Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center Talbot Hall, Columbus, OH, USAView further author information
,
W. Carson Felkelc Safe Point Harm Reduction Program, Equitas Health, Columbus, OH, USAView further author information
&
Julie Teatera Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center Talbot Hall, Columbus, OH, USAORCID Iconhttps://orcid.org/0000-0003-3497-1641View further author information
ORCID Icon show all
Pages 312-315 | Published online: 20 Oct 2023

References

  • Cohen, A. J., Klett, C. J., & Ling, W. (1983). Patient perspectives of opiate withdrawal. Drug and Alcohol Dependence, 12(2), 167–172. https://doi.org/10.1016/0376-8716(83)90041-8
  • Enos, G. (2019). Koob: Understanding negative reinforcers of opioids could uncover new treatments. Alcoholism & Drug Abuse Weekly, 31(33), 1–7. https://doi.org/10.1002/adaw.32467
  • George, O., Koob, G. F., & Vendruscolo, L. F. (2014). Negative reinforcement via motivational withdrawal is the driving force behind the transition to addiction. Psychopharmacology, 231(19), 3911–3917. https://doi.org/10.1007/s00213-014-3623-1
  • Goldberg, S. R., Hoffmeister, F., Schlichting, U., & Wuttke, W. (1971). Aversive properties of nalorphine and naloxone in morphine-dependent rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics, 179(2), 268–276.
  • Greenwald, M. K., Herring, A. A., Perrone, J., Nelson, L. S., & Azar, P. (2022). A neuropharmacological model to explain buprenorphine induction challenges. Annals of Emergency Medicine, 80(6), 509–524. https://doi.org/10.1016/j.annemergmed.2022.05.032
  • Hutcheson, D. M., Everitt, B. J., Robbins, T. W., & Dickinson, A. (2001). The role of withdrawal in heroin addiction: Enhances reward or promotes avoidance? Nature Neuroscience, 4(9), 943–947. https://doi.org/10.1038/nn0901-943
  • Koob, G. F. (2008). A role for brain stress systems in addiction. Neuron, 59(1), 11–34. https://doi.org/10.1016/j.neuron.2008.06.012
  • Koob, G. F. (2009). Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology, 56(Suppl 1), 18–31. https://doi.org/10.1016/j.neuropharm.2008.07.043
  • Koob, G. F. (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Research, 1314, 3–14. https://doi.org/10.1016/j.brainres.2009.11.008
  • Koob, G. F. (2013). Negative reinforcement in drug addiction: The darkness within. Current Opinion in Neurobiology, 23(4), 559–563. https://doi.org/10.1016/j.conb.2013.03.011
  • Koob, G. F. (2020). Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement. Biological Psychiatry, 87(1), 44–53. https://doi.org/10.1016/j.biopsych.2019.05.023
  • Koob, G. F. (2022). Anhedonia, hyperkatifeia, and negative reinforcement in substance use disorders. In D. A. Pizzagalli (Ed.), Anhedonia: Preclinical, translational, and clinical integration (Vol. 58, pp. 147–165). Springer International Publishing. https://doi.org/10.1007/7854_2021_288
  • Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238. https://doi.org/10.1038/npp.2009.110
  • Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. The Lancet, 3(8), 760–773. https://doi.org/10.1016/S2215-0366(16)00104-8
  • Mannelli, P., Douaihy, A. B., Zavod, A., Legedza, A., Akerman, S. C., & Sullivan, M. A. (2021). Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone. The American Journal of Drug and Alcohol Abuse, 47(6), 753–759. https://doi.org/10.1080/00952990.2021.1969659
  • Mucha, R. F., Gritti, M. D., & Kim, C. (1986). Aversive properties of opiate withdrawal studied in rats. NIDA Research Monograph, 75, 567–570.
  • Oakley, B., Wilson, H., Hayes, V., & Lintzeris, N. (2021). Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug and Alcohol Review, 40(4), 567–571. https://doi.org/10.1111/dar.13228
  • Pantazis, C. B., Gonzalez, L. A., Tunstall, B. J., Carmack, S. A., Koob, G. F., & Vendruscolo, L. F. (2021). Cues conditioned to withdrawal and negative reinforcement: Neglected but key motivational elements driving opioid addiction. Science Advances, 7(15), eabf0364. https://doi.org/10.1126/sciadv.abf0364
  • Substance Abuse and Mental Health Services Administration (SAMHSA). (2021). Key substance use and mental health indicators in the United States Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56).
  • Spadaro, A., Long, B., Koyfman, A., & Perrone, J. (2022). Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. The American Journal of Emergency Medicine, 58, 22–26. https://doi.org/10.1016/j.ajem.2022.05.013
  • Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. The New England Journal of Medicine, 374(4), 363–371. https://doi.org/10.1056/NEJMra1511480

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.